Search

Your search keyword '"Fiorentino, Michelangelo"' showing total 10 results
Start Over Author "Fiorentino, Michelangelo" Journal clinical genitourinary cancer
10 results on '"Fiorentino, Michelangelo"'

6. Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, and Real-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis

Author

Schiavina, Riccardo, Capizzi, Elisa, Borghesi, Marco, Vagnoni, Valerio, Romagnoli, Daniele, Rocca, Giovanni Christian, Giunchi, Francesca, D'Errico, Antonietta, De Giovanni, Alessia, Rizzi, Simona, Brunocilla, Eugenio, Martorana, Giuseppe, and Fiorentino, Michelangelo

Published
2015
Full Text
View/download PDF

9. Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, and Real-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis

Author

Schiavina, Riccardo, Capizzi, Elisa, Borghesi, Marco, Vagnoni, Valerio, Romagnoli, Daniele, Rocca, Giovanni Christian, Giunchi, Francesca, D'Errico, Antonietta, De Giovanni, Alessia, Rizzi, Simona, Brunocilla, Eugenio, Martorana, Giuseppe, and Fiorentino, Michelangelo

Abstract

A proper lymph node (LN) staging is of utmost importance to the patient's prognosis, and the prognostic importance of LN occult metastases (OCM) in the survival of the patients still remains a matter of debate. In our study, serial section (SS), immunohistochemistry (IHC), and real-time reverse transcriptase polymerase chain reaction (RT-PCR) detected a not negligible percentage of OCM missed at standard examination, thus improving LN staging and patient management.

Published
2024
Full Text
View/download PDF

10. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma

Author

Michelangelo Fiorentino, Elisabetta Nobili, Francesco Massari, Veronica Mollica, Riccardo Schiavina, Andrea Ardizzoni, Eugenio Brunocilla, Vincenzo Di Nunno, Di Nunno, Vincenzo, Mollica, Veronica, Schiavina, Riccardo, Nobili, Elisabetta, Fiorentino, Michelangelo, Brunocilla, Eugenio, Ardizzoni, Andrea, and Massari, Francesco

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Multivariate analysis, Urology, medicine.medical_treatment, 030232 urology & nephrology, Bone Neoplasms, Kaplan-Meier Estimate, Risk Assessment, Targeted therapy, Metastasis, Central Nervous System Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Renal cell carcinoma, Internal medicine, medicine, Humans, Medical history, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Proportional hazards model, business.industry, Liver Neoplasms, Hazard ratio, Middle Aged, Prognosis, medicine.disease, Kidney Neoplasms, Confidence interval, Immune checkpoint inhibitors Immunotherapy mRCC Prognostic models Targeted therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Female, business, Follow-Up Studies
Abstract

Background Several models are adopted in clinical practice to estimate prognosis of patients with metastatic renal cell carcinoma (mRCC); however, none of these models have evaluated patients treated by immune-checkpoint inhibitors. The aim of this study was to investigate if the site of initial metastasis could be a parameter able to stratified prognosis among patients with mRCC among different risk groups defined by the International Metastatic Renal Cell Database Consortium (IMDC) model. The site of initial metastasis was defined as the primary tissue or organ in which metastasis was diagnosed in the course of the medical history of the disease. Patients and Methods A total of 134 patients treated between January 2010 and December 2018 in our institution were retrospectively evaluated. The primary outcome was overall survival (OS) defined as the time from initiation of first-line therapy to death from any cause. Of note, 26 (19.4%) patients received immune-checkpoint inhibitors. Univariable analysis was performed through the log-rank test to estimate the effect of number of metastatic sites and site of initial metastasis on OS. Subsequently, a Cox regression proportional hazards model was employed in multivariable analysis. Results Of the 12 variables analyzed, 4 were statistically associated to worse OS in univariable analysis (number of metastases and liver, bone, or central nervous system metastases). Multivariate analysis confirmed that bone (hazard ratio [HR], 1.92; 95% confidence interval [CI], 1.17-3.13), liver (HR, 2.65; 95% CI, 1.59-4.42), and central nervous system (HR, 3.3; 95% CI, 1.62-6.74) initial metastases were independent parameters related to worse OS. The presence of 1 or more of the selected sites recognized specific populations of patients associated to worse prognosis in both good (P = .003) and intermediate (P = .047) risk groups. Conclusion The site of initial metastasis defines specific populations of patients associated with worse prognosis in the good and intermediate IMDC groups.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results